NLRP3 and breast carcinoma: In conclusion, inflammation emerges as a dominant force in promoting breast cancer occurrence, and NLRP3 inhibitory drugs, studied extensively to impede inflammasome activation, provide a new direction and hope for breast cancer treatment.